-
Jan 11, 2025 | 
cellandgene.com | Jackie Mulryne |Eftychia Sideri |Heba Jalil |Antony Hitchcock
With over 450 unique products in clinical development and 50 anticipated approvals by 2030, the evolving regulatory landscape for cell and gene therapies is more critical than ever. Don't miss your chance to gain expert insights! Join the next Cell & Gene Live for an exclusive digital panel discussion exploring forward-looking perspectives on this transformative field. Registration is free—thanks to the support of Thermo Fisher Scientific.
-
Dec 4, 2024 | 
cellandgene.com | Jackie Mulryne |Eftychia Sideri |Heba Jalil |Rich Buonaiuto Tree
On-Demand Webinar: Expanding CAR T Beyond OncologyCAR T therapies, known for bringing groundbreaking treatment advancements to oncology, are beginning to show promise in additional therapeutic areas. Watch our on-demand webinar to explore how collaboration between therapeutically aligned teams impacts study delivery for CAR T in autoimmune disease and neurology clinics.
-
Dec 1, 2024 | 
mondaq.com | Jackie Mulryne |Eftychia Sideri |Heba Jalil
On October 21, 2024, the Medicines and Healthcare products
Regulatory Agency (MHRA) announced that the U.K. will be the first
country in the world to introduce a tailored framework for the
manufacture of innovative medicines at or close to the location
where a patient receives care.
-
Nov 14, 2024 | 
bioprocessonline.com | Jackie Mulryne |Eftychia Sideri |Heba Jalil
By Jackie Mulryne, Eftychia Sideri, and Heba Jalil, Arnold & Porter
On October 21, 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that the U.K. will be the first country in the world to introduce a tailored framework for the manufacturer of innovative medicines at or close to the location where a patient receives care.
-
Nov 5, 2024 | 
mondaq.com | Jackie Mulryne |Eftychia Sideri
On 21 October 2024, the Medicines and Healthcare products
Regulatory Agency (MHRA) announced that the UK will be the first
country in the world to introduce a tailored framework for the
manufacture of innovative medicines at or close to the location
where a patient receives care.
-
Oct 8, 2024 | 
mondaq.com | Jackie Mulryne |Alexander Roussanov |Eftychia Sideri
AP
Arnold & Porter
More
Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
-
Sep 24, 2024 | 
mondaq.com | Jackie Mulryne |Alexander Roussanov |Eftychia Sideri
On 5 September 2024, the European Medicines Agency (EMA) and the
Heads of Medicine Agencies (HMA) published a guidance document (the Guidance) with general
principles and recommendations on the use of large language models
(LLMs) in regulatory science and the regulation of medicinal
products. The guiding principles for users are also summarised in a
one-page factsheet.
-
Jul 16, 2024 | 
mondaq.com | Jackie Mulryne
In the UK General Election on 4 July, the Labour Party won 412
of the 650 seats, giving it a comfortable majority. Its leader, Sir
Keir Starmer, became Prime Minister, meaning a change of government
from Conversative to Labour for the first time in 14 years.
In its campaign, Labour focused on the need to deliver economic
growth and innovation in critical industry sectors.
-
Apr 18, 2024 | 
mondaq.com | Jackie Mulryne |Alexander Roussanov
Members of the European Parliament (MEPs) have voted overwhelmingly in favour of the
pharmaceutical reform package following a debate on 10 April.
The vote is a key step in the passage of the new Directive and
Regulation, which together form the EU's revisions to the
General Pharmaceutical Legislation (GPL).
-
Apr 15, 2024 | 
lexblog.com | Jackie Mulryne |Alexander Roussanov
Members of the European Parliament (MEPs) have voted overwhelmingly in favour of the pharmaceutical reform package following a debate on 10 April. The vote is a key step in the passage of the new Directive and Regulation, which together form the EU’s revisions to the General Pharmaceutical Legislation (GPL).
